Abstract
BackgroundLittle is known about differences in work productivity (WP) and patient-reported outcomes (PROs) between rheumatoid arthritis (RA) patients (pts) maintained on adalimumab (ADA) and methotrexate (MTX) after achieving low disease...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have